GLP-1 therapies are moving beyond diabetes and obesity into MASH/NAFLD, cardiovascular risk reduction, and possibly neurodegenerative conditions
Our findings should enable the use of oligoureas in other peptides to improve their pharmaceutical properties and may provide new therapeutic applications
While many patients successfully use injectable medications, some people remain hesitant about regular injections
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al
[21] Anecdotally, however, many users have found that injecting themselves at different times of day can cause different levels of nausea
Our team of experienced plastic surgeons work closely with patients to get the best results